Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine M Tangen

Showing results (21-30 of 217) with videos related to

Pageof 22
Sort By:
Journal of the National Cancer Institute|February 26, 2011
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detectionAndrew J Vickers, Cathee Till, Catherine M Tangen, et al.
Urologic Oncology|March 28, 2008
Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancerSeth P Lerner, Catherine M Tangen, Heidi Sucharew, et al.
The Journal of Urology|April 18, 2007
Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancerSeth P Lerner, Catherine M Tangen, Heidi Sucharew, et al.
The Journal of Urology|November 13, 2004
Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894Tomasz M Beer, Catherine M Tangen, Lisa B Bland, et al.
The Journal of Urology|June 16, 2009
Chemoprevention of prostate cancerIan M Thompson, Catherine M Tangen, Phyllis J Goodman, et al.
Cancer Research|September 18, 2002
The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomyRobert A Gatenby, Edward T Gawlinski, Catherine M Tangen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2005
Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisitedEric A Klein, Catherine M Tangen, Phyllis J Goodman, et al.
Urology|May 6, 2008
Does the level of prostate cancer risk affect cancer prevention with finasteride?Ian M Thompson, Catherine M Tangen, Howard L Parnes, et al.
The Journal of Urology|December 23, 2008
Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949Primo N Lara, Catherine M Tangen, Sarah J Conlon, et al.
Urology|September 24, 2013
Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom scoreDonna P Ankerst, Cathee Till, Andreas Boeck, et al.
Pageof 22

Showing results (21-30 of 217) with videos related to

Sort By:
Pageof 22
Journal of the National Cancer Institute|February 26, 2011
An empirical evaluation of guidelines on prostate-specific antigen velocity in prostate cancer detectionAndrew J Vickers, Cathee Till, Catherine M Tangen, et al.
Urologic Oncology|March 28, 2008
Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancerSeth P Lerner, Catherine M Tangen, Heidi Sucharew, et al.
The Journal of Urology|April 18, 2007
Patterns of recurrence and outcomes following induction bacillus Calmette-Guerin for high risk Ta, T1 bladder cancerSeth P Lerner, Catherine M Tangen, Heidi Sucharew, et al.
The Journal of Urology|November 13, 2004
Prognostic value of anemia in newly diagnosed metastatic prostate cancer: a multivariate analysis of southwest oncology group study 8894Tomasz M Beer, Catherine M Tangen, Lisa B Bland, et al.
The Journal of Urology|June 16, 2009
Chemoprevention of prostate cancerIan M Thompson, Catherine M Tangen, Phyllis J Goodman, et al.
Cancer Research|September 18, 2002
The possible role of postoperative azotemia in enhanced survival of patients with metastatic renal cancer after cytoreductive nephrectomyRobert A Gatenby, Edward T Gawlinski, Catherine M Tangen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 15, 2005
Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisitedEric A Klein, Catherine M Tangen, Phyllis J Goodman, et al.
Urology|May 6, 2008
Does the level of prostate cancer risk affect cancer prevention with finasteride?Ian M Thompson, Catherine M Tangen, Howard L Parnes, et al.
The Journal of Urology|December 23, 2008
Predictors of survival of advanced renal cell carcinoma: long-term results from Southwest Oncology Group Trial S8949Primo N Lara, Catherine M Tangen, Sarah J Conlon, et al.
Urology|September 24, 2013
Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom scoreDonna P Ankerst, Cathee Till, Andreas Boeck, et al.
Pageof 22